Antigen News and Research

RSS

Celerus Diagnostics to present Wave RPD totally automated HC staining system at annual USCAP meeting

Celerus Diagnostics will introduce a totally automated immunohistochemistry (IHC) staining system, the much-anticipated Wave RPD, at the United States and Canadian Association of Pathologists (USCAP) annual meeting being held in Washington DC, March 22–24. The new system is the first of its kind, capable of delivering totally automated IHC results in one hour.

17 Mar 2010

Booster shot appears to improve TB resistance in previously vaccinated adults

A booster shot appears to improve tuberculosis (TB) resistance in previously vaccinated adults, according to new research in South Africa.

17 Mar 2010

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.

16 Mar 2010

Study suggests HuR gene plays a critical role in inducing cells' inflammatory response

To understand the role of inflammation in cardiovascular and other diseases, it is essential to identify and characterize genes that induce an inflammatory response in the body -- and the genes that regulate them.

16 Mar 2010

Study confirms blood-stage infection is due to population mixing and disease evolution

In a paradigm changing discovery, Plasmodium vivax (P. vivax) malaria has been identified in a population historically thought to be resistant to the disease, those who do not express the Duffy blood group protein on their red blood cells, according to researchers from Case Western Reserve University School of Medicine, Pasteur Institute, and the Madagascar Ministry of Health.

16 Mar 2010

StockPreacher.com announces investment report featuring Generex Biotechnology

StockPreacher.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.

11 Mar 2010

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).

11 Mar 2010

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.

11 Mar 2010

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

ImmunoCellular Therapeutics, Ltd. announced today that its dendritic cell-based vaccination with cancer stem cells demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium.

8 Mar 2010

Scientists identify the role of vitamin D in activation of T cells

Scientists at the University of Copenhagen have discovered that Vitamin D is crucial to activating our immune defenses and that without sufficient intake of the vitamin, the killer cells of the immune system - T cells - will not be able to react to and fight off serious infections in the body.

8 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

New anti-tumour vaccine for mesothelioma shows promising results

A vaccine against mesothelioma, a cancer associated with exposure to asbestos, has shown early promise in its first clinical trial.

5 Mar 2010

America's Prostate Cancer Organizations release shared perspective on screening and treatment

America's Prostate Cancer Organizations today released the full text of written testimony to the House Committee on Oversight and Government Reform. The Committee will be holding a hearing on "Prostate Cancer: New Questions About Screening and Treatment" on March 4, 2010.

5 Mar 2010

Men should discuss risks, benefits with doctor before undergoing prostate-cancer screening

Men who undergo prostate-cancer screening should discuss with a doctor the uncertainties, risks and benefits of the test before it is performed, says Edward Partridge, M.D., president-elect of the American Cancer Society National Board of Directors and director of the University of Alabama at Birmingham Comprehensive Cancer Center.

5 Mar 2010

Advaxis' Listeria based fusion protein granted U.S. patent

The US Patent and Trademark Office (USPTO) has issued Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent #7662396 titled “Compositions and Methods for Enhancing the Immunogenicity of Antigens” for the use of fusion proteins that have been found to be effective in numerous models for the treatment of cancer in the presence of immune tolerance.

5 Mar 2010

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).

5 Mar 2010

Antigen News and Research

Celerus Diagnostics to present Wave RPD totally automated HC staining system at annual USCAP meeting

Booster shot appears to improve TB resistance in previously vaccinated adults

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

Study suggests HuR gene plays a critical role in inducing cells' inflammatory response

Study confirms blood-stage infection is due to population mixing and disease evolution

StockPreacher.com announces investment report featuring Generex Biotechnology

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Scientists identify the role of vitamin D in activation of T cells

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

New anti-tumour vaccine for mesothelioma shows promising results

America's Prostate Cancer Organizations release shared perspective on screening and treatment

Men should discuss risks, benefits with doctor before undergoing prostate-cancer screening

Advaxis' Listeria based fusion protein granted U.S. patent

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics